RxDoctor Payments Data

Michelle Thomas, MD

Nephrology · Newnan, GANPI 1285155820

Payments from drug & device makers

$794in general payments, 2019–2025

Across 45 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$160
  • Vantive US Healthcare LLC$105
  • Novartis$89
  • Otsuka America Pharmaceutical, Inc.$89
  • Aurinia Pharma U.S., Inc.$64
  • Travere Therapeutics, Inc.$61
  • plus $226 from 7 others

What the payments were for

  • Food & beverage$69387%
  • Education$10113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$794 in reported general payments places this provider in the 35th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$133,273
Medicare patients
493
Services billed
1,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone19$18,282
FarxigaDapagliflozin Propanediol17$16,487
LokelmaSodium Zirconium Cyclosilicate12$6,077
Sevelamer Carbonate14$3,508
Torsemide18$1,169
Calcitriol56$959
Chlorthalidone55$586
Allopurinol61$530
Amlodipine Besylate79$385
Losartan Potassium39$289
Famotidine18$246
Hydralazine Hcl21$176
Nifedipine ErNifedipine12$173
Vitamin D2Ergocalciferol (Vitamin D2)17$164
Lisinopril35$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$17$22,56429 claims
BayerKerendia$23$18,28219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 388 nephrology providers in Georgia.

Other nephrology in Newnan

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →